statistiche ricercatore

DENTALI, FRANCESCO

Distribuzione geografica

Continente	#
NA - Nord America	24.252
EU - Europa	13.025
AS - Asia	3.023
Continente sconosciuto - Info sul continente non disponibili	33
SA - Sud America	29
OC - Oceania	8
AF - Africa	5
Totale	40.375

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	24.224
IT - Italia	6.716
UA - Ucraina	2.279
TR - Turchia	1.607
SE - Svezia	1.186
IE - Irlanda	796
DE - Germania	747
VN - Vietnam	731
CN - Cina	574
FI - Finlandia	501
GB - Regno Unito	419
FR - Francia	194
RU - Federazione Russa	59
IN - India	44
EU - Europa	29
CA - Canada	24
JP - Giappone	24
NL - Olanda	23
BE - Belgio	22
CZ - Repubblica Ceca	17
BR - Brasile	14
CL - Cile	11
ES - Italia	9
PT - Portogallo	8
AU - Australia	7
RO - Romania	7
SG - Singapore	7
AT - Austria	6
CH - Svizzera	6
GR - Grecia	6
HK - Hong Kong	5
HU - Ungheria	4
TH - Thailandia	4
A2 - ???statistics.table.value.countryCode.A2???	3
AL - Albania	3
AR - Argentina	3
EG - Egitto	3
ID - Indonesia	3
IL - Israele	3
IR - Iran	3
MY - Malesia	3
NO - Norvegia	3
PK - Pakistan	3
DK - Danimarca	2
HN - Honduras	2
KR - Corea	2
LI - Liechtenstein	2
PL - Polonia	2
RS - Serbia	2
SI - Slovenia	2
A1 - Anonimo	1
AE - Emirati Arabi Uniti	1
AZ - Azerbaigian	1
BA - Bosnia-Erzegovina	1
CR - Costa Rica	1
KW - Kuwait	1
KZ - Kazakistan	1
LA - Repubblica Popolare Democratica del Laos	1
LK - Sri Lanka	1
LT - Lituania	1
MD - Moldavia	1
MX - Messico	1
NG - Nigeria	1
NZ - Nuova Zelanda	1
PE - Perù	1
PH - Filippine	1
SA - Arabia Saudita	1
SK - Slovacchia (Repubblica Slovacca)	1
TW - Taiwan	1
UZ - Uzbekistan	1
ZA - Sudafrica	1
Totale	40.375

Salva come PNG Salva come JPEG

Città	#
Milan	4.988
Fairfield	4.108
Woodbridge	2.671
Ashburn	2.018
Houston	1.922
Jacksonville	1.808
Seattle	1.604
Wilmington	1.492
Chandler	1.387
Cambridge	1.384
Ann Arbor	1.312
Izmir	813
Dublin	791
Princeton	787
Dearborn	591
Nyköping	539
Dong Ket	367
Rome	313
San Diego	243
San Mateo	159
Ogden	152
Beijing	127
Como	126
Washington	102
London	95
New York	72
Düsseldorf	70
Hefei	62
Redmond	62
Nanjing	59
Los Angeles	56
Norwalk	53
Helsinki	50
Kunming	50
Verona	48
Kocaeli	39
Paris	37
Kilburn	30
Jinan	29
Boardman	28
Nanchang	24
Frankfurt am Main	23
Tokyo	22
Besana In Brianza	20
Falls Church	19
Ponte Lambro	19
Redwood City	19
Guangzhou	18
Prescot	18
Brussels	17
Fuzhou	17
Chiswick	16
Toronto	16
Brno	15
Chicago	15
Acton	14
Indiana	14
Shenyang	14
Varese	14
Berlin	13
Philadelphia	13
Bergamo	12
Hounslow	12
Busto Arsizio	11
Wandsworth	11
Hebei	10
New Bedfont	10
San Francisco	10
Southwark	10
Wuhan	10
Xian	10
Changsha	9
Dallas	9
Islington	9
Pune	9
Phoenix	8
Ralingen	8
Suresnes	8
São Paulo	8
Zhengzhou	8
Chongqing	7
Magnago	7
Ningbo	7
Torino	7
Abbiategrasso	6
Detroit	6
Hangzhou	6
Legnano	6
Munich	6
Saint Louis	6
Amsterdam	5
Andover	5
Baotou	5
Brescia	5
Cleveland	5
Lappeenranta	5
Novara	5
Parma	5
Quzhou	5
Shaoxing	5
Totale	31.300

Salva come PNG Salva come JPEG

Nome	#
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis	233
A survey of thrombosis prophylaxis use in patients undergoing arthroscopic surgery	222
Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature	221
Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency vka anticoagulation reversal	218
Risk of recurrence of unusual site venous thromboembolism	211
Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: A longitudinal study during atorvastatin treatment	195
PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis	192
Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome	192
Optimal treatment duration of venous thrombosis	188
incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio.	187
Impact of neutrophils to lymphocytes ratio on major clinical outcomes in patients with acute coronary syndromes: A systematic review and meta-analysis of the literature	186
Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry	185
Patient selection for thromboprophylaxis in medical inpatients	184
Diagnostic accuracy of lung ultrasound for pulmonary embolism: a systematic review and meta-analysis.	183
Association between ABCG2 and ABCB1 genes and warfarin stability: a case-control study	180
Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice	178
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism.	176
Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable?	176
Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis	176
Venous ischemic syndromes	176
Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data	174
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature	172
Prevalence and Clinical History of Incidental, Asymptomatic Pulmonary Embolism: A Meta-Analysis	172
Warfarin interactions with antibiotics in the ambulatory care setting	169
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation	169
Duration of anticoagulation after venous thromboembolism in real world clinical practice	168
Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism	168
A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study	167
Venous and arterial thrombosis in patients with HIV infection	166
Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens	166
Seasonal and monthly variation in occurrence of hypertensive urgency	165
Diagnostic accuracy of magnetic resonance imaging in patients with suspected pulmonary embolism: A bivariate meta-analysis	164
Factors associated with anticoagulation prescription in elderly patients with atrial fibrillation	162
Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis	161
Pulmonary embolism prognostic factors and length of hospital stay: A cohort study	161
Management of primary care patients with suspected deep vein thrombosis: use of a therapeutic dose of low-molecular-weight heparin to avoid urgent ultrasonographic evaluation.	161
Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature	160
Statins and secondary prevention of ischemic and hemorrhagic stroke	159
Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians	159
Pulmonary Embolism Severity Index Accurately Predicts Long-Term Mortality Rate In Patients Hospitalized For Acute Pulmonary Embolism	158
ABO blood group and vascular disease: an update	158
Gender Difference in Efficacy and Safety of Nonvitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation or Venous Thromboembolism: A Systematic Review and a Meta-Analysis of the Literature	158
Predictors of residual venous obstruction after deep vein thrombosis of the lower limbs: a prospective cohort study	157
Emergency reversal of anticoagulation with vitamin K antagonists with 3-factor prothrombin complex concentrates in patients with major bleeding	157
Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy	157
Low-molecular -weight heparin in pregnancies after ART -A retrospective study-	156
Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: do perfusion scintigraphy and angio-computed tomography agree?	154
Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage	154
Is diabetes a hypercoagulable state? A critical appraisal	154
The role of inherited thrombophilia in patients with isolated pulmonary embolism: a systematic review and a meta-analysis of the literature	153
Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: A multicenter retrospective cohort study	153
Intracranial bleeding risk after minor traumatic brain injury in patients on antithrombotic drugs	153
Brain natriuretic peptide and preclinical chronic thromboembolic pulmonary hypertension.	152
sRAGE and early signs of cardiac target organ damage in mild hypertensives	152
Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment	151
Low ankle-brachial index predicts an adverse 1-year outcome after acute coronary and cerebrovascular events	151
Prevention of in-hospital VTE: why can't we do better?	150
How I treat splanchnic vein thrombosis	150
The role of thrombolytic therapy in pulmonary embolism	150
Statins for acute ischemic stroke	150
In vitro effects of Apixaban on 5 different cancer cell lines	149
Antithrombotic and fibrinolytic drugs for retinal vein occlusion: a systematic review and a call for action.	148
The initial phase of oral anticoagulation with warfarin in outpatients with deep venous thrombosis.	147
Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism: Comment	147
In-hospital mortality due to pulmonary embolism in patients with Alzheimer disease: A sex effect?	147
The effect of thyroid autoantibodies on warfarin stability	147
Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE Study	146
Italian intersociety consensus on DOAC use in internal medicine	145
Clinical utility of antithrombotic prophylaxis in ART procedures: an Italian experience	144
Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes	144
Association between the metabolic syndrome, its individual components, and unprovoked venous thromboembolism: Results of a patient-level meta-analysis	144
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature: a reply to a rebuttal	143
Direct oral anticoagulants for superficial-vein thrombosis	143
The prevention and treatment of venous thromboembolism in pregnancy	143
Atypical case of Acute Coronary Syndrome due to Coronary-Pulmonary Steal Syndrome secondary to Pulmonary Embolism.	142
Management of hypertension in overweight and obese patients: a practical guide for clinicians.	142
Clinical Pregnancies and Live Births in women approaching ART: a follow-up analysis of 157 women after thrombophilia screening	142
Neutrophil-to-lymphocyte ratio: A new prognostic factor even in patients with heart failure	142
Antithrombin levels and the risk of a first episode of venous thromboembolism: a case-control study	141
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy	141
Metabolic syndrome and hyperhomocysteinemia in patients with deep vein thrombosis: a case-control study	140
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases	140
Inferior vena cava filter in patients with venous thromboembolism and major bleeding events: building the evidence	140
Risk of Thromboembolism, Recurrent Hemorrhage, and Death after Warfarin Therapy Interruption for Gastrointestinal Tract Bleeding	140
Nonadherence with INR monitoring and anticoagulant complications	139
A prospective validation of the Bova score in normotensive patients with acute pulmonary embolism	138
JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis.	138
A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program.	137
Natural anticoagulants deficiency and the risk of venous thromboembolism: A meta-analysis of observational studies	137
Venous thromboembolism and arterial thromboembolism. Many similarities, far beyond thrombosis per se.	136
Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study.	135
Short-term prognosis of intracranial haemorrhage in patients on oral anticoagulant or antiplatelet drugs	135
The role of the metabolic syndrome in patients with provoked venous thromboembolic events	135
Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry	135
Statins, fibrates, and venous thromboembolism: a meta-analysis.	134
Evaluation of right ventricular function in patients with a previous episode of pulmonary embolism using tissue Doppler imaging.	134
American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients	134
Prevalence of renal failure and use of antithrombotic prophylaxis among medical inpatients at increased risk of venous thromboembolic events.	133
JAK2V617F mutation in patients with arterial thrombosis in the absence of overt myeloproliferative disease.	132
Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism: A multicentre retrospective cohort study	132
Totale	15.841

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	157.778
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	157.778

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2019/2020	8.877	404	394	476	1.754	653	965	1.231	1.043	721	571	169	496
2020/2021	7.056	145	653	766	695	409	732	291	619	838	458	574	876
2021/2022	4.033	403	544	187	104	219	172	325	215	229	726	411	498
2022/2023	4.345	480	206	318	379	303	956	14	560	651	238	132	108
2023/2024	8.115	1.241	1.276	1.284	1.554	1.634	559	57	105	238	74	34	59
2024/2025	21	21	0	0	0	0	0	0	0	0	0	0	0
Totale													40.875